These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 75547)

  • 1. Periodic loss of reactivity of a myeloma tumor with cytotoxic thymus-derived lymphocytes.
    Russell JH; Hale AH; Ginns LC; Eisen HN
    Proc Natl Acad Sci U S A; 1978 Jan; 75(1):441-5. PubMed ID: 75547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of reactivity of a BALB/c myeoloma tumor with allogeneic and syngeneic cytotoxic T lymphocytes.
    Russel JH; Hale AH; Inbar D; Eisen HN
    Eur J Immunol; 1978 Sep; 8(9):640-5. PubMed ID: 309400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of reactivity of a myeloma tumor with H-2 compatible thymus-derived lymphocytes.
    Hale AH; Paulus LK
    Cell Immunol; 1979 Sep; 46(2):337-47. PubMed ID: 226273
    [No Abstract]   [Full Text] [Related]  

  • 4. Periodic fluctuations in resistance of a myeloma tumor (MOPC-315-el) to cytotoxic T lymphocytes.
    Hale AH; Russell JH; d'Angeac AD; Panetti M; Hazelton B; Eisen HN
    Cell Immunol; 1981 Jul; 62(1):119-31. PubMed ID: 6973405
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies on monoclonal antibodies to mouse MHC products.
    Ozato K; Epstein SL; Henkart P; Hansen TH; Sachs DH
    Transplant Proc; 1981 Mar; 13(1 Pt 2):958-62. PubMed ID: 6168076
    [No Abstract]   [Full Text] [Related]  

  • 6. Cyclical changes in susceptibility of a myeloma tumor (LPC-1) to immune destruction. I. Changes in reactivity with cytotoxic T lymphocytes and anti-H-2d sera.
    Celis E; Hale AH; Russell JH; Eisen HN
    J Immunol; 1979 Mar; 122(3):954-8. PubMed ID: 312828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T lymphocyte-mediated suppression of myeloma function in vitro. III. Regulation of antibody production in hybrid myeloma cells by T lymphocytes.
    Abbas AK; Burakoff SJ; Gefter ML; Greene MI
    J Exp Med; 1980 Oct; 152(4):969-78. PubMed ID: 6158552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloma proteins as tumor-specific transplantation antigens.
    Lynch RG; Graff RJ; Sirisinha S; Simms ES; Eisen HN
    Proc Natl Acad Sci U S A; 1972 Jun; 69(6):1540-4. PubMed ID: 4113870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cell-mediated cytolysis of trinitrophenyl-derivatized target cells by alloantisera directed to the products of the K and D loci of the H-2 complex.
    Burakoff SJ; Germain RN; Dorf ME; Benacerrah B
    Proc Natl Acad Sci U S A; 1976 Feb; 73(2):625-9. PubMed ID: 1082140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hybrid cell lines secreting monoclonal antibody specific for major histocompatibility antigens of the mouse.
    Lemke H; Hammerling GJ; Hohmann C; Rajewsky K
    Nature; 1978 Jan; 271(5642):249-51. PubMed ID: 74805
    [No Abstract]   [Full Text] [Related]  

  • 11. H-2 antigens incorporated into phospholipid vesicles elicit specific allogeneic cytotoxic T lymphocytes.
    Hale AH
    Cell Immunol; 1980 Oct; 55(2):328-41. PubMed ID: 6159109
    [No Abstract]   [Full Text] [Related]  

  • 12. Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state.
    Weinhold KJ; Wheelock EF
    Cancer Res; 1982 Sep; 42(9):3607-16. PubMed ID: 6179603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclical changes in susceptibility of a myeloma tumor (LPC-1) to immune destruction. III. Periodic production of a cell surface glycoprotein and changes in reactivity with cytotoxic T cells and anti-H-2d sera.
    Celis E; Chang TW; Eisen HN
    J Immunol; 1979 Jun; 122(6):2245-50. PubMed ID: 312862
    [No Abstract]   [Full Text] [Related]  

  • 14. Alloimmune cytotoxic T cells: Evidence that they recognize serologically defined antigens and bear clonally restricted receptors.
    Bevan MJ
    J Immunol; 1975 Jan; 114(1 Pt 2):316-9. PubMed ID: 123256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of syngeneic tumor tRNA on MOPC 315 myeloma in BALB-cCR mouse.
    Brugarolas A; Takita H; Elias EG; Mittelman A; Luch J
    J Surg Oncol; 1973; 5(2):97-100. PubMed ID: 4703847
    [No Abstract]   [Full Text] [Related]  

  • 16. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
    Bartik MM; Takesue BY; Mokyr MB
    Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoic acid stimulation of the induction of mouse killer T-cells in allogeneic and syngeneic systems.
    Dennert G; Crowley C; Kouba J; Lotan R
    J Natl Cancer Inst; 1979 Jan; 62(1):89-94. PubMed ID: 309967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LY-2+ effectors cytotoxic for syngeneic tumor cells: generation by allogeneic stimulation and by supernatants from mixed leukocyte cultures.
    Hurrell SM; Zarling JM
    J Immunol; 1983 Aug; 131(2):1017-23. PubMed ID: 6223084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration of cell-surface antigenicity of the mouse plasmacytoma. I. Immunologic characterization of surface antigens masked during successive transplantations.
    Ono S; Natsu-ume S; Migita S
    J Natl Cancer Inst; 1975 Sep; 55(3):569-77. PubMed ID: 51090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idiotype-specific T lymphocytes. I. Regulation of antibody production by idiotype-specific H-2-restricted T lymphocytes.
    Yamamoto H; Bitoh S; Torii M; Fujimoto S
    J Immunol; 1983 Mar; 130(3):1038-42. PubMed ID: 6185567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.